IMPORTANCE: Colorectal cancer (CRC) screening saves lives, but participation rates are low among underserved populations. Knowledge on effective approaches for screening the underserved, including best test type to offer, is limited. OBJECTIVE: To determine (1) if organized mailed outreach boosts CRC screening compared with usual care and (2) if FIT is superior to colonoscopy outreach for CRC screening participation in an underserved population. DESIGN, SETTING, AND PARTICIPANTS: We identified uninsured patients, not up to date with CRC screening, age 54 to 64 years, served by the John Peter Smith Health Network, Fort Worth and Tarrant County, Texas, a safety net health system. INTERVENTIONS: Patients were assigned randomly to 1 of 3 groups. One group was assigned to fecal immunochemical test (FIT) outreach, consisting of mailed invitation to use and return an enclosed no-cost FIT (n = 1593). A second was assigned to colonoscopy outreach, consisting of mailed invitation to schedule a no-cost colonoscopy (n = 479). The third group was assigned to usual care, consisting of opportunistic primary care visit–based screening (n = 3898). In addition, FIT and colonoscopy outreach groups received telephone follow-up to promote test completion. MAIN OUTCOME MEASURES: Screening participation in any CRC test within 1 year after randomization. RESULTS:Mean patient age was 59 years; 64% of patients were women. The sample was 41% white, 24% black, 29% Hispanic, and 7% other race/ethnicity. Screening participation was significantly higher for both FIT (40.7%) and colonoscopy outreach (24.6%) than for usual care (12.1%) (P < .001 for both comparisons with usual care). Screening was significantly higher for FIT than for colonoscopy outreach (P < .001). In stratified analyses, screening was higher for FIT and colonoscopy outreach than for usual care, and higher for FIT than for colonoscopy outreach among whites, blacks, and Hispanics (P < .005 for all comparisons). Rates of CRC identification and advanced adenoma detection were 0.4% and 0.8% for FIT outreach, 0.4% and 1.3% for colonoscopy outreach, and 0.2% and 0.4% for usual care, respectively (P < .05 for colonoscopy vs usual care advanced adenoma comparison; P > .05 for all other comparisons). Eleven of 60 patients with abnormal FIT results did not complete colonoscopy. CONCLUSIONS AND REVELANCE: Among underserved patients whose CRC screening was not up to date, mailed outreach invitations resulted in markedly higher CRC screening compared with usual care. Outreach was more effective with FIT than with colonoscopy invitation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01191411.
RCT Entities:
IMPORTANCE: Colorectal cancer (CRC) screening saves lives, but participation rates are low among underserved populations. Knowledge on effective approaches for screening the underserved, including best test type to offer, is limited. OBJECTIVE: To determine (1) if organized mailed outreach boosts CRC screening compared with usual care and (2) if FIT is superior to colonoscopy outreach for CRC screening participation in an underserved population. DESIGN, SETTING, AND PARTICIPANTS: We identified uninsured patients, not up to date with CRC screening, age 54 to 64 years, served by the John Peter Smith Health Network, Fort Worth and Tarrant County, Texas, a safety net health system. INTERVENTIONS:Patients were assigned randomly to 1 of 3 groups. One group was assigned to fecal immunochemical test (FIT) outreach, consisting of mailed invitation to use and return an enclosed no-cost FIT (n = 1593). A second was assigned to colonoscopy outreach, consisting of mailed invitation to schedule a no-cost colonoscopy (n = 479). The third group was assigned to usual care, consisting of opportunistic primary care visit–based screening (n = 3898). In addition, FIT and colonoscopy outreach groups received telephone follow-up to promote test completion. MAIN OUTCOME MEASURES: Screening participation in any CRC test within 1 year after randomization. RESULTS: Mean patient age was 59 years; 64% of patients were women. The sample was 41% white, 24% black, 29% Hispanic, and 7% other race/ethnicity. Screening participation was significantly higher for both FIT (40.7%) and colonoscopy outreach (24.6%) than for usual care (12.1%) (P < .001 for both comparisons with usual care). Screening was significantly higher for FIT than for colonoscopy outreach (P < .001). In stratified analyses, screening was higher for FIT and colonoscopy outreach than for usual care, and higher for FIT than for colonoscopy outreach among whites, blacks, and Hispanics (P < .005 for all comparisons). Rates of CRC identification and advanced adenoma detection were 0.4% and 0.8% for FIT outreach, 0.4% and 1.3% for colonoscopy outreach, and 0.2% and 0.4% for usual care, respectively (P < .05 for colonoscopy vs usual care advanced adenoma comparison; P > .05 for all other comparisons). Eleven of 60 patients with abnormal FIT results did not complete colonoscopy. CONCLUSIONS AND REVELANCE: Among underserved patients whose CRC screening was not up to date, mailed outreach invitations resulted in markedly higher CRC screening compared with usual care. Outreach was more effective with FIT than with colonoscopy invitation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01191411.
Authors: Judith M E Walsh; Rene Salazar; Tung T Nguyen; Celia Kaplan; Lam Kieu Nguyen; Jimmy Hwang; Stephen J McPhee; Rena J Pasick Journal: Am J Prev Med Date: 2010-07 Impact factor: 5.043
Authors: Carrie N Klabunde; Kathleen A Cronin; Nancy Breen; William R Waldron; Anita H Ambs; Marion R Nadel Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-06-08 Impact factor: 4.254
Authors: Karen E Lasser; Jennifer Murillo; Sandra Lisboa; A Naomie Casimir; Lisa Valley-Shah; Karen M Emmons; Robert H Fletcher; John Z Ayanian Journal: Arch Intern Med Date: 2011-05-23
Authors: Enrique Quintero; Antoni Castells; Luis Bujanda; Joaquín Cubiella; Dolores Salas; Ángel Lanas; Montserrat Andreu; Fernando Carballo; Juan Diego Morillas; Cristina Hernández; Rodrigo Jover; Isabel Montalvo; Juan Arenas; Eva Laredo; Vicent Hernández; Felipe Iglesias; Estela Cid; Raquel Zubizarreta; Teresa Sala; Marta Ponce; Mercedes Andrés; Gloria Teruel; Antonio Peris; María-Pilar Roncales; Mónica Polo-Tomás; Xavier Bessa; Olga Ferrer-Armengou; Jaume Grau; Anna Serradesanferm; Akiko Ono; José Cruzado; Francisco Pérez-Riquelme; Inmaculada Alonso-Abreu; Mariola de la Vega-Prieto; Juana Maria Reyes-Melian; Guillermo Cacho; José Díaz-Tasende; Alberto Herreros-de-Tejada; Carmen Poves; Cecilio Santander; Andrés González-Navarro Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: Ronald E Myers; Randa Sifri; Terry Hyslop; Michael Rosenthal; Sally W Vernon; James Cocroft; Thomas Wolf; Jocelyn Andrel; Richard Wender Journal: Cancer Date: 2007-11-01 Impact factor: 6.860
Authors: Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz Journal: Ann Intern Med Date: 2008-10-06 Impact factor: 25.391
Authors: Samir Gupta; Daniel A Sussman; Chyke A Doubeni; Daniel S Anderson; Lukejohn Day; Amar R Deshpande; B Joseph Elmunzer; Adeyinka O Laiyemo; Jeanette Mendez; Ma Somsouk; James Allison; Taft Bhuket; Zhuo Geng; Beverly B Green; Steven H Itzkowitz; Maria Elena Martinez Journal: J Natl Cancer Inst Date: 2014-03-28 Impact factor: 13.506
Authors: Sarah L Cutrona; Joann Wagner; Douglas W Roblin; Bridget Gaglio; Andrew Williams; Rosalie Torres-Stone; Kathleen M Mazor Journal: J Health Commun Date: 2015-04-03
Authors: Jamie H Thompson; Melinda M Davis; Michael C Leo; Jennifer L Schneider; David H Smith; Amanda F Petrik; Melissa Castillo; Brittany Younger; Gloria D Coronado Journal: Contemp Clin Trials Date: 2018-02-09 Impact factor: 2.226
Authors: Ronald E Myers; Randa Sifri; Constantine Daskalakis; Melissa DiCarlo; Praveen Ramakrishnan Geethakumari; James Cocroft; Christopher Minnick; Nancy Brisbon; Sally W Vernon Journal: J Natl Cancer Inst Date: 2014-12-06 Impact factor: 13.506
Authors: Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex Journal: Am J Gastroenterol Date: 2016-10-18 Impact factor: 10.864
Authors: Gloria D Coronado; William M Vollmer; Amanda Petrik; Stephen H Taplin; Timothy E Burdick; Richard T Meenan; Beverly B Green Journal: Contemp Clin Trials Date: 2014-06-14 Impact factor: 2.226
Authors: Caitlin C Murphy; Sally W Vernon; Nicole M Haddock; Melissa L Anderson; Jessica Chubak; Beverly B Green Journal: Prev Med Date: 2014-06-15 Impact factor: 4.018